AAA
RAPT

Affinity Asset Advisors’s RAPT Therapeutics RAPT Stock Holding History

Affinity Asset Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-68,125
Closed -$1.66M – 102
2024
Q2 		$1.66M Sell
68,125
-4,013
-6% -$185K 0.19% 68
2024
Q1 		$5.18M Buy
+72,138
New +$10M 0.64% 48

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Affinity Asset Advisors's RAPT Position: Q1 2025 in Review

Affinity Asset Advisors sold out of RAPT Therapeutics (RAPT) in Q1 2025, closing a stake of 125,000 shares — an estimated $1.58M sold.

Affinity Asset Advisors first reported a position in RAPT in Q2 2024 and held it in 2 quarters. The position peaked at $1.58M in Q4 2024. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

  • Affinity Asset Advisors reported no remaining RAPT Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 125,000 RAPT Therapeutics shares in Q1 2025, an estimated $1.58M.
  • Affinity Asset Advisors first reported a position in RAPT Therapeutics in Q2 2024 and held it in 2 quarters.
  • Affinity Asset Advisors's RAPT Therapeutics position peaked at $1.58M in Q4 2024.
  • 92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on Affinity Asset Advisors's 13F filing for Q1 2025, filed 14 May 2025.